查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1541095

2024-2032 年按治療類型、配方、應用、最終用戶和地區分類的製藥連續製造市場報告

Pharmaceutical Continuous Manufacturing Market Report by Therapeutics Type, Formulation, Application, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年，全球製藥連續製造市場規模達13億美元。對有效藥品生產系統的需求不斷成長、製藥行業的改進、研發（R＆D）活動的​​增加以及不斷升級的健康問題是推動市場的一些因素。

藥品連續生產代表了藥物和疫苗生產的整體方法，可提高創新藥品的品質和一致性，同時需要最少的資本投資。與傳統的批次相比，這種方法在連續流中無縫運行，提供可擴展性、增強的控制、自動化和消除物理干預。值得注意的是，連續藥品製造顯著減少了藥物配製時間和人為錯誤的可能性，增強了生產過程監控，並確保產品品質符合嚴格的監管標準。因此，該技術被製藥公司和合約製造組織 (CMO) 廣泛採用，用於開發活性藥物成分 (API) 和藥物。藥品連續生產的採用凸顯了其在提高藥品生產效率和遵守法規要求方面的關鍵作用。

在幾個關鍵因素的推動下，全球市場正在經歷強勁成長。對藥品和疫苗的需求不斷成長，特別是在全球健康挑戰持續存在的情況下，迫使該行業提高生產效率。連續製造簡化了流程，縮短了交貨時間，並確保了更可靠的藥品供應，使其成為滿足這一日益成長的需求的有吸引力的解決方案。此外，連續製造的成本效益是一個重要的促進因素。與傳統的批量製程相比，它需要的資本投資更低，這使其成為尋求最佳化營運同時最大限度降低費用的製藥公司的有吸引力的選擇。此外，監管機構越來越支持連續生產，因為它具有提高產品品質、降低污染風險和提供生產過程即時監控的潛力。這種與監管指南的一致性鼓勵更多的製藥公司採用連續生產實務。此外，連續生產生產具有更高一致性和純度的高品質藥品的能力是一個關鍵因素。此技術可最大限度地減少人為錯誤，確保對關鍵參數的精確控制，並降低交叉污染的風險。此外，製藥連續製造透過最大限度地減少浪費和能源消耗來實現永續發展目標，這與致力於對環境更加負責的生產流程的公司產生了共鳴。

製藥連續製造市場趨勢/促進因素：

多種慢性病的盛行率日益上升

慢性病的日益普及是市場不斷擴大的重要動力。糖尿病、心血管疾病和各種癌症等慢性疾病在全球呈現上升趨勢。慢性健康問題的大幅增加創造了對藥物和藥物的持續需求。連續生產為慢性病日益成長的藥物需求提供了更有效、更敏感的解決方案。其精簡且連續的生產流程確保了基本藥物的可靠和持續供應，降低了短缺風險並改善了患者獲得治療的機會。此外，隨著製藥公司努力生產治療慢性病的複雜藥物和生物製劑，連續生產為藥物生產提供了更好的控制和精確度。這對於確保這些挽救生命的治療的品質和功效至關重要。

增加研發 (R&D) 活動

對研發（R&D）活動的​​日益重視是藥品連續製造市場成長的強大推動力。製藥公司正大力投資研發，開發新藥、生物製品和疫苗，以應對各種健康挑戰，包括傳染病、慢性病和新出現的健康威脅。連續製造透過提供更有效率、更受控的生產流程來與這些研發工作保持一致。它使製藥公司能夠迅速擴大新候選藥物的生產規模，並縮短創新療法的上市時間。在應對全球健康危機或流行病時，這種生產靈活性尤其有價值，其中疫苗和治療方法的快速開發和製造至關重要。此外，連續生產有助於藥物配方的最佳化和新型藥物輸送方法的探索，這都是藥物研發的重要方面。和品質。隨著製藥業不斷創新並推出新療法，連續製造技術的採用預計將進一步成長，這得益於其與當代研發活動需求的一致性。

人工智慧 (AI) 解決方案的整合度不斷提高

人工智慧 (AI) 解決方案的不斷整合是推動製藥連續製造市場成長的強大推動力。人工智慧技術正在徹底改變藥物研究、開發和製造的各個方面。在製藥連續製造中，人工智慧用於流程最佳化和自動化。人工智慧驅動的演算法可以即時監控和調整關鍵製造參數，確保產品品質一致並降低偏差風險。這種自動化程度提高了效率並最大限度地減少了製造過程中的人為錯誤。人工智慧也應用於藥物發現和配方。機器學習演算法分析大量資料集，以識別潛在的候選藥物、預測其行為並最佳化其配方，以獲得更好的功效和安全性。這加速了藥物開發，並使製藥公司能夠更快地將新療法推向市場。此外，人工智慧驅動的預測性維護可以幫助製藥製造商主動識別和解決設備問題，最大限度地減少停機時間和生產中斷。隨著製藥公司認知到人工智慧在提高效率、降低成本和提高產品品質方面的潛力，他們擴大在連續製造過程中採用人工智慧解決方案。這種整合符合產業對先進技術的追求，以滿足不斷變化的醫療保健需求，從而推動藥品連續製造市場的成長。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球製藥連續製造市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依治療類型

  • 大分子
    • 市場趨勢
    • 市場預測
  • 小分子
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：按配方

  • 固體製劑
    • 市場趨勢
    • 市場預測
  • 液體和半固體製劑
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：按應用

  • 最終藥品製造
    • 市場趨勢
    • 市場預測
  • 原料藥製造
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按最終用戶

  • 製藥公司
    • 市場趨勢
    • 市場預測
  • 合約製造組織
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Baker Perkins
    • Coperion GmbH (Hillenbrand Inc.)
    • Eli Lilly and Company
    • GEA Group Aktiengesellschaft
    • Glatt GmbH
    • Korsch AG
    • Novartis AG
    • Siemens
    • SK biotek
    • Thermo Fisher Scientific Inc.
    • Viatris Inc.
Product Code: SR112024A5935

The global pharmaceutical continuous manufacturing market size reached US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.2 Billion by 2032, exhibiting a growth rate (CAGR) of 10.1% during 2024-2032. The rising demand for effective medicine production systems, the improvements in the pharmaceutical sector, the increasing research and development (R&D) activities, and the escalating health concerns are some of the factors propelling the market.

Pharmaceutical continuous manufacturing represents a holistic approach to drug and vaccine production that elevates the quality and consistency of innovative pharmaceuticals while requiring minimal capital investment. In contrast to traditional batch processing, this method operates seamlessly in a continuous flow, offering scalability, increased control, automation, and the elimination of physical interventions. Notably, continuous pharmaceutical manufacturing significantly reduces drug formulation time and the potential for human errors, enhances production process monitoring, and ensures product quality aligns with stringent regulatory standards. As a result, this technique is widely embraced by pharmaceutical companies and contract manufacturing organizations (CMOs) to develop active pharmaceutical ingredients (APIs) and medications. The adoption of pharmaceutical continuous manufacturing underscores its pivotal role in advancing pharmaceutical production efficiency and compliance with regulatory requirements.

The global market is experiencing robust growth driven by several key factors. The increasing demand for pharmaceuticals and vaccines, particularly with the ongoing global health challenges, has pressured the industry to improve production efficiency. Continuous manufacturing streamlines the process, reduces lead times, and ensures a more reliable supply of medicines, making it an attractive solution to meet this heightened demand. Furthermore, the cost-effectiveness of continuous manufacturing is a significant driver. It requires lower capital investments than traditional batch processes, making it an appealing choice for pharmaceutical companies looking to optimize their operations while minimizing expenses. Moreover, regulatory agencies are increasingly supportive of continuous manufacturing due to its potential to enhance product quality, reduce contamination risks, and provide real-time monitoring of the production process. This alignment with regulatory guidelines encourages more pharmaceutical companies to adopt continuous manufacturing practices. Additionally, the ability of continuous manufacturing to produce high-quality pharmaceuticals with greater consistency and purity is a crucial factor. This technology minimizes human errors, ensures precise control over critical parameters, and reduces the risk of cross-contamination. Besides, pharmaceutical continuous manufacturing aligns with sustainability goals by minimizing waste and energy consumption, which resonates with companies aiming for more environmentally responsible production processes.

Pharmaceutical Continuous Manufacturing Market Trends/Drivers:

The growing prevalence of several chronic ailments

The growing prevalence of chronic ailments is a significant driver behind the expanding market. Chronic diseases, such as diabetes, cardiovascular conditions, and various cancers, are rising globally. This considerable rise in chronic health issues has created a sustained demand for pharmaceuticals and medications. Continuous manufacturing offers a more efficient and responsive solution to the increasing medication requirements for chronic diseases. Its streamlined and continuous production process ensures a reliable and consistent supply of essential drugs, reducing the risk of shortages and improving patient access to treatments. Furthermore, as pharmaceutical companies strive to produce complex medications and biologics for chronic conditions, continuous manufacturing provides greater control and precision in drug production. This is crucial in ensuring the quality and efficacy of these life-saving treatments.

Increasing research and development (R&D) activities

The increasing emphasis on research and development (R&D) activities is a powerful driving force behind the growth of the pharmaceutical continuous manufacturing market. Pharmaceutical companies are investing significantly in R&D to develop new drugs, biologics, and vaccines to address various health challenges, including infectious diseases, chronic conditions, and emerging health threats. Continuous manufacturing aligns with these R&D efforts by offering a more efficient and controlled production process. It enables pharmaceutical companies to swiftly scale up the manufacturing of new drug candidates, reducing time-to-market for innovative therapies. This agility in production is particularly valuable when responding to global health crises or pandemics, where the rapid development and manufacturing of vaccines and treatments are critical. Moreover, continuous manufacturing facilitates the optimization of drug formulations and the exploration of novel drug delivery methods, both essential aspects of pharmaceutical R&D By reducing production variability and ensuring precise control over critical parameters, it enhances the consistency and quality of experimental drugs. As the pharmaceutical industry continues to innovate and introduce novel therapies, the adoption of continuous manufacturing technologies is expected to grow further, bolstered by its alignment with the demands of contemporary R&D activities.

Rising integration of artificial intelligence (AI) solutions

The rising integration of artificial intelligence (AI) solutions is a compelling driver fueling the growth of the pharmaceutical continuous manufacturing market. AI technologies are revolutionizing various pharmaceutical research, development, and manufacturing aspects. In pharmaceutical continuous manufacturing, AI is used for process optimization and automation. AI-driven algorithms can monitor and adjust critical manufacturing parameters in real time, ensuring consistent product quality and reducing the risk of deviations. This level of automation enhances efficiency and minimizes human errors in the manufacturing process. AI is also employed in drug discovery and formulation. Machine learning algorithms analyze vast datasets to identify potential drug candidates, predict their behavior, and optimize their formulations for better efficacy and safety. This accelerates drug development and enables pharmaceutical companies to bring new therapies to market more quickly. Furthermore, AI-driven predictive maintenance can help pharmaceutical manufacturers proactively identify and address equipment issues, minimizing downtime and production disruptions. As pharmaceutical companies recognize the potential of AI in improving efficiency, reducing costs, and enhancing product quality, they are increasingly adopting AI solutions in their continuous manufacturing processes. This integration aligns with the industry's pursuit of advanced technologies to meet evolving healthcare demands, thereby driving the growth of the pharmaceutical continuous manufacturing market.

Pharmaceutical Continuous Manufacturing Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global pharmaceutical continuous manufacturing market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on therapeutics type, formulation, application, and end user.

Breakup by Therapeutics Type:

Large Molecules

Small Molecules

Small Molecules dominates the market

The report has provided a detailed breakup and analysis of the market based on the therapeutics type. This includes large molecules and small molecules. According to the report, small molecules represented the largest segment.

Small molecule drugs, including chemically synthesized pharmaceuticals, benefit from continuous manufacturing. It enhances the production efficiency of small molecule drugs, reduces production costs, and ensures product quality. As pharmaceutical companies seek cost-effective and efficient solutions for producing both generic and innovative small-molecule drugs, the adoption of continuous manufacturing in this segment remains robust.

Conversely, the production of large molecules, including biologics such as monoclonal antibodies and therapeutic proteins, requires highly precise and controlled manufacturing processes. Continuous manufacturing offers an advantage in producing these complex molecules with consistent quality. The biopharmaceutical industry, in particular, is increasingly turning to continuous manufacturing to meet the growing demand for biologics. This segment's adoption drives the market's growth as it aligns with the expanding biopharmaceutical sector.

Breakup by Formulation:

Solid Formulation

Liquid and Semi-solid Formulation

Solid Formulation dominates the market

The report has provided a detailed breakup and analysis of the market based on the formulation. This includes solid formulation, and liquid and semi-solid formulation. According to the report, solid formulation represented the largest segment.

Continuous manufacturing is particularly well-suited for solid dosage forms such as tablets, capsules, and powders. This segment leverages the benefits of continuous processes, including precise control over blending, granulation, and tableting. Pharmaceutical companies adopting continuous manufacturing for solid formulations experience enhanced efficiency, reduced waste, and improved consistency in producing oral solid medications. As the demand for solid dosage forms remains high, the continuous manufacturing approach significantly caters to this demand and optimizes production processes.

On the other hand, continuous manufacturing also benefits the production of liquid and semi-solid formulations, including syrups, suspensions, and creams. In this segment, continuous manufacturing streamlines mixing, blending, and filling processes. It enables pharmaceutical companies to achieve higher levels of automation, consistency, and quality control in manufacturing liquid and semi-solid medications. The adoption of continuous manufacturing in this category addresses the demand for various delivery forms and supports the development of innovative drug formulations.

Breakup by Application:

Final Drug Product Manufacturing

API Manufacturing

Final Drug Product Manufacturing dominates the market

The report has provided a detailed breakup and analysis of the market based on the application. This includes final drug product manufacturing and API manufacturing. According to the report, final drug product manufacturing represented the largest segment.

Continuous manufacturing offers a streamlined and efficient process for producing the final drug products, such as tablets, capsules, or injectables. This segment benefits from continuous processes that enhance precision and consistency in dosage form production. The adoption of continuous manufacturing in final drug product manufacturing results in cost savings, quicker time-to-market, and improved product quality, all of which drive market growth.

On the contrary, API manufacturing, the production of the active pharmaceutical ingredients that form the basis of medications, also benefits from continuous manufacturing practices. Continuous synthesis and processing of APIs ensure efficient and consistent production. Pharmaceutical companies adopting continuous manufacturing for API manufacturing experience increased yield, reduced waste, and quicker API production, thus contributing to market growth.

Breakup by End User:

Pharmaceutical Companies

Contract Manufacturing Organizations

Others

Pharmaceutical Companies dominates the market

The report has provided a detailed breakup and analysis of the market based on the end user. This includes pharmaceutical companies, contract manufacturing organizations, and others. According to the report, pharmaceutical companies represented the largest segment.

Pharmaceutical companies are major drivers of the adoption of continuous manufacturing. They utilize continuous processes for in-house production, focusing on enhancing efficiency, reducing costs, and ensuring consistent product quality. Continuous manufacturing aligns with their goal of delivering innovative, cost-effective pharmaceutical products, driving market growth.

Furthermore, contract manufacturing organizations specialize in providing manufacturing services to pharmaceutical companies, often on a contract basis. Continuous manufacturing is increasingly attractive to CMOs, enabling them to offer their clients more efficient and responsive production solutions. By adopting continuous manufacturing practices, CMOs can optimize their operations, reduce production lead times, and maintain high-quality standards, thus attracting more pharmaceutical clients and contributing to market growth.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America, comprising the United States and Canada, is a leading pharmaceutical innovation and production hub. Several factors contribute to the growth of pharmaceutical continuous manufacturing in this region. It is at the forefront of technological advancements in pharmaceutical manufacturing. Companies in this region continually invest in cutting-edge continuous manufacturing technologies, pushing the boundaries of efficiency and quality.

Regulatory bodies in North America are increasingly supportive of continuous manufacturing practices. This alignment with regulatory guidelines encourages pharmaceutical companies to adopt continuous manufacturing solutions, bolstering market growth. The region hosts numerous industry collaborations and consortiums focusing on advancing continuous manufacturing practices. These partnerships accelerate innovation and standardization within the sector.

Moreover, the pharmaceutical market in North America is vast and competitive. Companies in this region actively seek ways to improve efficiency, reduce costs, and enhance product quality, making continuous manufacturing an attractive option. Besides, pharmaceutical companies and contract manufacturing organizations have a significant global presence. Their adoption of continuous manufacturing helps disseminate these practices to other regions, further expanding the market.

Competitive Landscape:

Top companies are bolstering market growth through various strategic initiatives and innovations. They invest heavily in research and development to enhance continuous manufacturing technologies. They continually innovate and improve processes to offer more efficient, scalable, and precise manufacturing solutions. These companies collaborate closely with regulatory agencies to ensure that their continuous manufacturing processes meet the stringent requirements and quality standards set forth by regulatory bodies. This alignment instills trust and confidence in their solutions. Top firms form strategic partnerships with other pharmaceutical companies, contract manufacturers, and technology providers. These collaborations foster the development of integrated and standardized continuous manufacturing solutions that can be widely adopted across the industry. Furthermore, they offer educational resources and training programs to help pharmaceutical professionals effectively understand and implement continuous manufacturing technologies. This accelerates adoption and ensures the proper utilization of these systems. Leading companies expand internationally, addressing the global demand for advanced pharmaceutical manufacturing solutions. Their global reach helps in disseminating continuous manufacturing practices across regions.

The report has provided a comprehensive analysis of the competitive landscape in the pharmaceutical continuous manufacturing market. Detailed profiles of all major companies have also been provided.

Baker Perkins

Coperion GmbH (Hillenbrand Inc.)

Eli Lilly and Company

GEA Group Aktiengesellschaft

Glatt GmbH

Korsch AG

Novartis AG

Siemens

SK biotek

Thermo Fisher Scientific Inc.

Viatris Inc.

Recent Developments:

In 2023, Hillenbrand, Inc. successfully completed its acquisition of LINXIS Group, a leader in specialized equipment for the food, pharma, and cosmetics industries.

Eli Lilly and Company has successfully completed the acquisition of Versanis Bio in 2023, expanding its portfolio to include bimagrumab, a potential innovative treatment for obesity.

Viatris and Mapi Pharma have announced that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for GA Depot 40 mg, a long-acting glatiramer acetate being investigated as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis (RMS). The FDA has set a target action date of March 8, 2024, for the NDA.

Key Questions Answered in This Report

  • 1. How big is the global pharmaceutical continuous manufacturing market?
  • 2. What is the expected growth rate of the global pharmaceutical continuous manufacturing market during 2024-2032?
  • 3. What are the key factors driving the global pharmaceutical continuous manufacturing market?
  • 4. What has been the impact of COVID-19 on the global pharmaceutical continuous manufacturing market?
  • 5. What is the breakup of the global pharmaceutical continuous manufacturing market based on the therapeutics type?
  • 6. What is the breakup of the global pharmaceutical continuous manufacturing market based on formulation?
  • 7. What is the breakup of the global pharmaceutical continuous manufacturing market based on the application?
  • 8. What is the breakup of the global pharmaceutical continuous manufacturing market based on the end user?
  • 9. What are the key regions in the global pharmaceutical continuous manufacturing market?
  • 10. Who are the key players/companies in the global pharmaceutical continuous manufacturing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmaceutical Continuous Manufacturing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapeutics Type

  • 6.1 Large Molecules
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Small Molecules
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Formulation

  • 7.1 Solid Formulation
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Liquid and Semi-solid Formulation
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Final Drug Product Manufacturing
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 API Manufacturing
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Contract Manufacturing Organizations
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Baker Perkins
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Coperion GmbH (Hillenbrand Inc.)
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Eli Lilly and Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 GEA Group Aktiengesellschaft
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Glatt GmbH
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Korsch AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Novartis AG
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Siemens
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 SK biotek
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 Thermo Fisher Scientific Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Viatris Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials

List of Figures

  • Figure 1: Global: Pharmaceutical Continuous Manufacturing Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Therapeutics Type (in %), 2023
  • Figure 5: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Formulation (in %), 2023
  • Figure 6: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Pharmaceutical Continuous Manufacturing (Large Molecules) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Pharmaceutical Continuous Manufacturing (Large Molecules) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Pharmaceutical Continuous Manufacturing (Small Molecules) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Pharmaceutical Continuous Manufacturing (Small Molecules) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Pharmaceutical Continuous Manufacturing (Solid Formulation) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Pharmaceutical Continuous Manufacturing (Solid Formulation) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Pharmaceutical Continuous Manufacturing (Liquid and Semi-solid Formulation) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Pharmaceutical Continuous Manufacturing (Liquid and Semi-solid Formulation) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Pharmaceutical Continuous Manufacturing (Final Drug Product Manufacturing) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Pharmaceutical Continuous Manufacturing (Final Drug Product Manufacturing) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Pharmaceutical Continuous Manufacturing (API Manufacturing) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Pharmaceutical Continuous Manufacturing (API Manufacturing) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Pharmaceutical Continuous Manufacturing (Pharmaceutical Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Pharmaceutical Continuous Manufacturing (Pharmaceutical Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Pharmaceutical Continuous Manufacturing (Contract Manufacturing Organizations) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Pharmaceutical Continuous Manufacturing (Contract Manufacturing Organizations) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Pharmaceutical Continuous Manufacturing (Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Pharmaceutical Continuous Manufacturing (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: North America: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: North America: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: United States: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: United States: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Canada: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Canada: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Asia-Pacific: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Asia-Pacific: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: China: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: China: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Japan: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Japan: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: India: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: India: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: South Korea: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: South Korea: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Australia: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Australia: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Indonesia: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Indonesia: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Others: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Others: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Europe: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Europe: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Germany: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Germany: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: France: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: France: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: United Kingdom: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: United Kingdom: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Italy: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Italy: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Spain: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Spain: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Russia: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Russia: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Others: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Others: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Latin America: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Latin America: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Brazil: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Brazil: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Mexico: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Mexico: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Others: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Others: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Middle East and Africa: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Middle East and Africa: Pharmaceutical Continuous Manufacturing Market: Breakup by Country (in %), 2023
  • Figure 75: Middle East and Africa: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Global: Pharmaceutical Continuous Manufacturing Industry: SWOT Analysis
  • Figure 77: Global: Pharmaceutical Continuous Manufacturing Industry: Value Chain Analysis
  • Figure 78: Global: Pharmaceutical Continuous Manufacturing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmaceutical Continuous Manufacturing Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Therapeutics Type (in Million US$), 2024-2032
  • Table 3: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Formulation (in Million US$), 2024-2032
  • Table 4: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Pharmaceutical Continuous Manufacturing Market: Competitive Structure
  • Table 8: Global: Pharmaceutical Continuous Manufacturing Market: Key Players